Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase
Zoetis (NYSE:ZTS) was given a new $140.00 price target on by analysts at HSBC Holdings plc.
Zoetis (NYSE:ZTS) was upgraded by analysts at Barclays PLC to a "hold" rating.
Zoetis (NYSE:ZTS) is now covered by analysts at Barclays PLC. They set a "neutral" rating on the stock.
Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats [Yahoo! Finance]